NEW YORK, July 15, 2024 /PRNewswire/ -- A recent survey by MedFluencers has highlighted a significant shift in how healthcare professionals (HCPs) are turning to social media for pharmaceutical education and patient engagement. MedFluencers, an HCP influencer marketing agency founded by physicians, surveyed HCPs across 15 specialties, revealing insights into their interactions with pharmaceutical and medical device companies on social media.
The US Court of Appeals for the District of Columbia Circuit on Friday dismissed a case brought by the Federal Trade Commission against Endo Pharmaceuticals and Impax Laboratories, affirming a lower court ruling that rejected the commission’s claims that the competitor companies created an exclusionary agreement around the opioid Opana ER (oxymorphone extended release).
Enforcement Report - Week of June 7, 2023
Endo has certainly captured the public's imagination with its Peyronie's disease campaigns before, but, this time, it’s playing it straight.
Seven state attorneys general and a court-appointed bankruptcy federal watchdog are opposing up to $94 million in pre-bankruptcy bonuses paid to top executives and other insiders at opioid drug firm Endo International in Chester County, court documents show.
J&J will pay about $70 million in a lump-sum payment, which is the same amount as what Alabama would’ve received in a national settlement, but it’ll be paid out in one year instead of 9 years, the AG said. J&J also recently agreed to pay West Virginia $99 million as part of another opioid-related settlement.
DUBLIN, March 28, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping premixed Ephedrine Sulfate Injection in a ready-to-use 50 mg/10 ml single-use vial.
DUBLIN, March 3, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today honored select team members from across the world who exemplify Endo's Values as part of its inaugural Living Our Values Award program.
DUBLIN, Feb. 28, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2021 and introduced first-quarter 2022 financial guidance.